[HTML][HTML] Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial

CL Corless, KV Ballman, CR Antonescu… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
CL Corless, KV Ballman, CR Antonescu, V Kolesnikova, RG Maki, PWT Pisters…
Journal of Clinical Oncology, 2014ncbi.nlm.nih.gov
Purpose The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance)
study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib
prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST).
We sought to determine the pathologic and molecular factors associated with patient
outcome.
Abstract
Purpose
The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the pathologic and molecular factors associated with patient outcome.
ncbi.nlm.nih.gov